Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Drops By 48.0%

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 103,447 shares, a decline of 48.0% from the April 30th total of 199,019 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average daily volume of 324,989 shares, the short-interest ratio is presently 0.3 days.

Capstone Therapeutics Trading Up 4.9%

CAPS traded up $0.02 during trading on Monday, hitting $0.34. The company’s stock had a trading volume of 747,304 shares, compared to its average volume of 2,601,567. Capstone Therapeutics has a twelve month low of $0.26 and a twelve month high of $2.07. The company has a quick ratio of 0.29, a current ratio of 0.95 and a debt-to-equity ratio of 0.79. The stock’s fifty day moving average price is $0.47 and its 200-day moving average price is $0.63. The firm has a market capitalization of $4.24 million, a P/E ratio of -0.10 and a beta of -1.54.

Capstone Therapeutics (NASDAQ:CAPS) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Capstone Therapeutics had a negative net margin of 41.26% and a negative return on equity of 114.15%. The business had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.80 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent filing with the SEC. 2.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings cut Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.